Intensity Therapeutics Inc. (INTS)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Intensity Therapeutics Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Intensity Therapeutics Inc. (INTS) has returned -42.66% so far this year and -88.06% over the past 12 months.

Based on dividend-adjusted daily data since Jun 30, 2023, INTS's average daily return is +0.15%, while the average monthly return is +1.07%. At this rate, your investment would double in approximately 5.4 years.

Historically, 27% of months were positive and 73% were negative. The best month was Dec 2023 with a return of +249.7%, while the worst month was Apr 2025 at -70.2%. The longest winning streak lasted 2 consecutive months, and the longest losing streak was 7 months.

On a daily basis, INTS closed higher 43% of trading days. The best single day was Oct 30, 2025 with a return of +394.6%, while the worst single day was Jun 12, 2025 at -44.7%.

Intensity Therapeutics Inc. has an annualized alpha of 49.78%, beta of -0.14, and R² of 0.00 versus S&P 500 Index. Calculated based on daily prices since July 03, 2023.

• This stock participated in 361.17% of S&P 500 Index downside but only 11.91% of its upside — more exposed to losses than it benefited from rallies.
• Beta of -0.14 may look defensive, but with R² of 0.00 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R² of 0.00 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

INTS ranks 34 for risk / return — below 34% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The table below present risk-adjusted performance metrics for Intensity Therapeutics Inc. (INTS) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Intensity Therapeutics Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Intensity Therapeutics Inc. was 97.74%, occurring on Feb 17, 2026. The portfolio has not yet recovered.

The current Intensity Therapeutics Inc. drawdown is 97.62%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Intensity Therapeutics Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Intensity Therapeutics Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.